Evome Medical Technologies Inc. LNDZF
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -49.89% | -37.58% | 13.35% | 44.37% | 88.01% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -49.89% | -37.58% | 13.35% | 44.37% | 88.01% |
| Cost of Revenue | -48.77% | -35.21% | 24.04% | 28.99% | 69.60% |
| Gross Profit | -51.80% | -42.19% | -3.83% | 84.90% | 130.68% |
| SG&A Expenses | -55.53% | -47.87% | 40.56% | 21.08% | 104.37% |
| Depreciation & Amortization | -32.94% | -30.63% | 11.10% | 49.78% | 159.23% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -50.18% | -39.56% | 28.62% | 27.55% | 84.00% |
| Operating Income | 55.82% | 52.71% | -262.94% | 46.55% | -30.22% |
| Income Before Tax | -137.70% | -100.33% | -164.37% | -83.84% | 129.82% |
| Income Tax Expenses | -100.00% | 405.88% | -- | 100.25% | 130.34% |
| Earnings from Continuing Operations | -137.82% | -100.95% | -158.61% | -213.61% | 129.82% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.82% | -100.95% | -158.61% | -213.61% | 129.82% |
| EBIT | 55.82% | 52.71% | -262.94% | 46.55% | -30.22% |
| EBITDA | 2.32% | 60.36% | -1,165.35% | 68.55% | 73.81% |
| EPS Basic | -132.17% | -50.00% | -87.31% | -138.83% | 120.89% |
| Normalized Basic EPS | -75.76% | 41.33% | -73.00% | 109.42% | 58.75% |
| EPS Diluted | -132.17% | -50.00% | -87.31% | -138.83% | 120.49% |
| Normalized Diluted EPS | -75.76% | 41.33% | -73.00% | 109.42% | 58.75% |
| Average Basic Shares Outstanding | 16.91% | 33.71% | 37.94% | 31.37% | 42.85% |
| Average Diluted Shares Outstanding | 16.91% | 33.71% | 37.94% | 31.37% | 42.85% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |